2.40 USD
↗ 0.00 (0.00%)AT CLOSE (03:59 PM EDT)
Editas Medicine, Inc. Common Stock
EDITNASDAQ • USD
2.40
↗ 0.00 (0.17%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
2.40
↗ 0.00 (0.17%)
Market: CLOSED
Editas Medicine, Inc. Common Stock (EDIT) trades at $2.41 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, EDIT trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Oct 26, 2026.
Open?$2.39
High?$2.45
Low?$2.36
Prev. Close?$2.40
Volume?1.4M
Avg. Volume?2.9M
VWAP?$2.40
Rel. Volume?0.47x
Bid / Ask
Bid?$2.02 × 100
Ask?$2.83 × 100
Spread?$0.81
Midpoint?$2.43
Valuation & Ratios
Market Cap?368.6M
Shares Out?153.6M
Float?148.8M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?3.50
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
368.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?40
Z-Score?0
Momentum?85
Short Sent.?10
Piotroski F-Score?4/9Mixed
Altman Z-Score?-8.29Distress
Confidence?51%Low
Short InterestSqueeze Risk
Short % of Float?25.66%Squeeze Risk
Short Interest?38.2M
Days to Cover?14.3
Free Float148.8M
Avg Daily Volume2.7M
Settlement Date2026-10-15
Financial Health
Current Ratio?3.19Strong
Quick Ratio?3.19Strong
Cash Ratio?2.66Strong
Debt/Equity?0.53Moderate
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?3.50FAIR▾
Peers25
S&P49
P/S?7.84HIGH▾
Peers100
S&P14
P/FCF?N/A▾
EV/EBITDA?-3.0CHEAP▾
S&P97
EV/Sales?5.16FAIR▾
Peers100
S&P35
Returns & Efficiency
ROE?-70.2%WEAK▾
S&P3
ROA?-31.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-120550000
Enterprise Value?$242.5M
Fundamentals ratios updated end of day